These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 34554237)

  • 1. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
    JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nomogram incorporating treatment data for predicting overall survival in gastroenteropancreatic neuroendocrine tumors: a population-based cohort study.
    Wu Z; Shang G; Zhang K; Wang W; Fan M; Lin R
    Int J Surg; 2024 Apr; 110(4):2178-2186. PubMed ID: 38241384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomogram individually predicts the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms.
    Fang C; Wang W; Feng X; Sun J; Zhang Y; Zeng Y; Wang J; Chen H; Cai M; Lin J; Chen M; Chen Y; Li Y; Li S; Chen J; Zhou Z
    Br J Cancer; 2017 Nov; 117(10):1544-1550. PubMed ID: 28949958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a nomogram for predicting the overall survival of patients with gastroenteropancreatic neuroendocrine neoplasms.
    Xie S; Li L; Wang X; Li L
    Medicine (Baltimore); 2021 Jan; 100(2):e24223. PubMed ID: 33466202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors, prognostic factors, and nomograms for distant metastases in patients with gastroenteropancreatic neuroendocrine tumors: a population-based study.
    Li X; Fan Y; Tong J; Lou M
    Front Endocrinol (Lausanne); 2024; 15():1264952. PubMed ID: 38449852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
    Mosquera C; Koutlas NJ; Fitzgerald TL
    Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
    Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
    JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic nomogram based on the metastatic lymph node ratio for gastric neuroendocrine tumour: SEER database analysis.
    Li J; Lin Y; Wang Y; Lin H; Lin F; Zhuang Q; Lin X; Wu J
    ESMO Open; 2020 Apr; 5(2):. PubMed ID: 32253246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastroenteropancreatic neuroendocrine tumors in Iceland: a population-based study.
    Gudmundsdottir H; Möller PH; Jonasson JG; Björnsson ES
    Scand J Gastroenterol; 2019 Jan; 54(1):69-75. PubMed ID: 30638086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence Trends of Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Lee MR; Harris C; Baeg KJ; Aronson A; Wisnivesky JP; Kim MK
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2212-2217.e1. PubMed ID: 30580091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a nomogram model to predict survival outcomes in patients with primary hepatic neuroendocrine tumors based on SEER database.
    Zhang Z; Zhao X; Li Z; Wu Y; Liu Y; Li Z; Li G
    BMC Cancer; 2021 May; 21(1):567. PubMed ID: 34006241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
    Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
    BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
    Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
    Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence, survival, and prognostic nomogram of patients with small intestinal neuroendocrine tumors: A SEER population-based study.
    Peng Y; Xu B; Zhang F; Wu R; Tong S; Mao Z
    Medicine (Baltimore); 2024 Sep; 103(37):e39616. PubMed ID: 39287239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nomogram predicting overall survival of rectal squamous cell carcinomas patients based on the SEER database: A population-based STROBE cohort study.
    Diao JD; Wu CJ; Cui HX; Bu MW; Yue D; Wang X; Liu YL; Yang YJ
    Medicine (Baltimore); 2019 Nov; 98(46):e17916. PubMed ID: 31725640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of 320 gastroenteropancreatic neuroendocrine tumors identifies TS expression as independent biomarker for survival.
    Lee HS; Chen M; Kim JH; Kim WH; Ahn S; Maeng K; Allegra CJ; Kaye FJ; Hochwald SN; Zajac-Kaye M
    Int J Cancer; 2014 Jul; 135(1):128-37. PubMed ID: 24347111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Nomogram to Predict Individual Survival of Patients with Liver-Limited Metastases from Gastroenteropancreatic Neuroendocrine Neoplasms: A US Population-Based Cohort Analysis and Chinese Multicenter Cohort Validation Study.
    Xu G; Xiao Y; Hu H; Jin B; Wu X; Wan X; Zheng Y; Xu H; Lu X; Sang X; Ge P; Mao Y; Cai J; Zhao H; Du S
    Neuroendocrinology; 2022; 112(3):263-275. PubMed ID: 33902058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and survival trends for gastric neuroendocrine neoplasms: An analysis of 3523 patients in the SEER database.
    Cao LL; Lu J; Lin JX; Zheng CH; Li P; Xie JW; Wang JB; Chen QY; Lin M; Tu RH; Huang CM
    Eur J Surg Oncol; 2018 Oct; 44(10):1628-1633. PubMed ID: 29983275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of treatment center volume on outcomes in gastroenteropancreatic neuroendocrine tumor patients.
    Baeg K; Harris C; Naparst MS; Ahn E; Thapi S; Martin J; Rustgi S; Mhango G; Wisnivesky J; Kim MK
    BMC Cancer; 2021 Feb; 21(1):146. PubMed ID: 33563241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiological Data and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: Insights From Tertiary Referral Hospitals in Latvia.
    Ptasnuka M; Ozolins A; Narbuts Z; Truskovs A; Sperga M; Plaudis H
    World J Surg; 2020 Feb; 44(2):585-593. PubMed ID: 31605174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.